Genix Pharmaceuticals Corporation (GENPF) Stock
Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals. Their product pipeline features several key developments: Flu-X: An herbal treatment available as an oral solution or spray, targeting viral infections, influenza, and coronaviruses responsible for common colds. Renochlor: A nutritional supplement formulated to support the revitalization and maintenance of kidney health and function. Sucanon: An insulin sensitizer designed to reduce blood sugar by improving the sensitivity of muscle, fat, and liver cells to insulin. Beyond these, Genix Pharmaceuticals also offers a wide range of other nutraceuticals and pharmaceutical items. This selection includes supplements such as bee propolis capsules, liquid calcium softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, alongside ophthalmic products like eye ointments and drops. The company operated under the name Alta Natural Herbs & Supplements Ltd. until it adopted its current identity, Genix Pharmaceuticals Corporation, in June 2019.
Genix Pharmaceuticals Corporation is headquartered in CA.
Genix Pharmaceuticals Corporation (GENPF) stock trades at $0.01 with a market capitalization of $844893. The stock is valued at a price-to-earnings (P/E) ratio of -6.45, price-to-book of -0.76, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.04, and currently trades 75.0% below its 52-week high.
On profitability, Genix Pharmaceuticals Corporation generates a return on equity (ROE) of 19.27%, above the typical market average, return on capital employed of 7.47%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.genixpharm.com